PMID- 18080853
OWN - NLM
STAT- MEDLINE
DCOM- 20080514
LR  - 20211020
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 255
IP  - 1
DP  - 2008 Jan
TI  - Hyperhomocysteinemia is associated with cognitive impairment in multiple 
      sclerosis.
PG  - 64-9
AB  - Hyperhomocysteinemia (HHcy) has been associated with cognitive impairment in 
      various neurological diseases. Cognitive impairment occurs early in multiple 
      sclerosis (MS). Conflicting data have been reported regarding plasma total 
      homocysteine (tHcy) levels in MS patients, and the impact of HHcy on cognitive 
      impairment in MS is not known. This study investigated whether plasma total 
      homocysteine levels are increased in MS and if HHcy is associated with cognitive 
      impairment in MS. We compared tHcy levels in 94 patients with MS and 53 healthy 
      age-matched controls. We used a neuropsychological test battery that included the 
      Raven's Coloured Progressive Matrices, the Visual Search Test, the Trail Making 
      Test A and B, the Immediate and Delayed Recall of a Short Story, the 30 Paired 
      Word Associates, the Rey-Osterrieth Complex Figure Test, and the Semantic and 
      Verbal Fluency Tests. Clinical (sex, age, type of MS, relapse, disease duration, 
      coexisting disease, smoking habit, and physical disability) and laboratory 
      variables (HHcy, low serum levels of folate and vit.B12, MTHFR genotype) were 
      evaluated for their ability to predict cognitive impairment. The mean tHcy was 
      higher in patients (13.19 micromol/L, SD5.58) than in controls (9.81 micromol/L, 
      SD2.53; p < 0.001). Univariate analysis determined the following factors to be 
      associated with cognitive impairment: higher age at observation, chronic 
      progressive course of disease, longer disease duration,moderate or severe 
      physical disability, and frequency of HHcy. With multivariate regression 
      analysis, there remained a significant association only between frequency of HHcy 
      and cognitive impairment (beta 0.262, p = 0.01). We conclude that tHcy levels are 
      increased in MS and that HHcy is associated with cognitive impairment in this 
      disease.
FAU - Russo, C
AU  - Russo C
AD  - Neurologic Unit, Azienda Ospedaliera, Bianchi-Melacrino-Morelli, Reggio Calabria, 
      Italy.
FAU - Morabito, F
AU  - Morabito F
FAU - Luise, F
AU  - Luise F
FAU - Piromalli, A
AU  - Piromalli A
FAU - Battaglia, L
AU  - Battaglia L
FAU - Vinci, A
AU  - Vinci A
FAU - Trapani Lombardo, V
AU  - Trapani Lombardo V
FAU - de Marco, V
AU  - de Marco V
FAU - Morabito, P
AU  - Morabito P
FAU - Condino, F
AU  - Condino F
FAU - Quattrone, A
AU  - Quattrone A
FAU - Aguglia, Umberto
AU  - Aguglia U
LA  - eng
PT  - Journal Article
DEP - 20071220
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Age of Onset
MH  - Brain/metabolism/physiopathology
MH  - Cognition Disorders/*blood/*etiology/physiopathology
MH  - Disability Evaluation
MH  - Disease Progression
MH  - Folic Acid/blood
MH  - Homocysteine/blood
MH  - Hyperhomocysteinemia/*blood/*complications/physiopathology
MH  - Multiple Sclerosis/*blood/*complications/psychology
MH  - Multivariate Analysis
MH  - Neuropsychological Tests
MH  - Predictive Value of Tests
MH  - Up-Regulation/physiology
MH  - Vitamin B 12 Deficiency/blood/complications/physiopathology
EDAT- 2007/12/18 09:00
MHDA- 2008/05/15 09:00
CRDT- 2007/12/18 09:00
PHST- 2007/02/12 00:00 [received]
PHST- 2007/06/05 00:00 [accepted]
PHST- 2007/05/08 00:00 [revised]
PHST- 2007/12/18 09:00 [pubmed]
PHST- 2008/05/15 09:00 [medline]
PHST- 2007/12/18 09:00 [entrez]
AID - 10.1007/s00415-007-0668-7 [doi]
PST - ppublish
SO  - J Neurol. 2008 Jan;255(1):64-9. doi: 10.1007/s00415-007-0668-7. Epub 2007 Dec 20.